Recruiting clinical trials in CH

back button

Bemarituzumab

anti-FGFR2b Antibody
Phase 1b/2
Monotherapy
Indication
Solid Tumors with
FGFR2b Overexpression
FORTITUDE-301
A Phase 1b/2, multicenter, Open-label Basket Study evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression
Amgen protocol ID 20210104
Status Switzerland
Recruiting
Centers, PIs:
KSGR, M. Mark ✉︎
HUG, T. Kössler ✉︎
Bemarituzumab

anti-FGFR2b Antibody
Phase 1b/3
Combination therapy
mFOLFOX6 + nivolumab
Indication
Gastric or GEJ cancer
FORTITUDE-102
Bemarituzumab plus chemotherapy and nivolumab versus chemotherapy and nivolumab alone in subjects with previously untreated advanced G/GEJ cancer with FGFR2b overexpression
Amgen protocol ID 20210098
Status Switzerland
Recruiting
Centers, PIs:
USB,
V. Hess ✉︎
Inselspital, M. Berger ✉︎
USZ, R. Fritsch ✉︎
HUG, T. Kössler ✉︎
KSGR, S. Bastian ✉︎
Onkozentrum Zürich, S. Hendrich
Sotorasib

KRAS G12C Inhibitor
Phase 3
Combination therapy
platinum doublet
Indication
NSCLC
code202
Sotorasib platinum doublet combination versus pembrolizumab platinum doublet combination as a front-line therapy in participants with stage IV or advanced stage IIIB/C nonsquamous Non-Small Cell Lung Cancer, negative for PD-L1
Amgen protocol ID 20190341
Status Switzerland
Recruiting
Centers, PIs:
USB,
D. König ✉︎
KSB, S. Rothschild
KSA, W.D. Janthur
Tarlatamab
(AMG 757)


DLL3 x CD3 Half-life extended Bispecific T-Cell Engager
Phase 1b
Combination therapy
carboplatin,
etoposide + PD-L1 inhibitor
Indication
ES-SCLC
dellphi-303
A Phase 1b Study Evaluating the Safety and Efficacy of First-line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Patients With Extensive-Stage Small Cell Lung Cancer
Amgen protocol ID 20200469
Status Switzerland
Recruiting
Centers, PIs:
Inselspital, S. Häfliger ✉︎
USB, D. König ✉︎
Tarlatamab
(AMG 757)


DLL3 x CD3 Half-life extended Bispecific T-Cell Engager
Phase 3
Combination therapy with Durvalumab
Indication
ES-SCLC
dellphi-304
A study comparing tarlatamab in combination with durvalumab versus durvalumab alone in subjects with extensive-Stage Small-Cell lung Cancer following platinum, etoposide and durvalumab.
Amgen protocol ID 20200041
Status Switzerland
Recruiting
Centers, PIs:
KSB, D. König ✉︎
IOSI, P. Frösch
AMG 794

CLDN6 x CD3 Half-life extended Bispecific T-Cell Engager
Phase 1
Monotherapy
Indication
CLDN6 positive
solid tumors
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 794 in Subjects With Claudin 6-positive Advanced/Metastatic Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications
Amgen protocol ID 20210007
Status Switzerland
Not yet recruiting
Centers, PIs:
Inselspital, S. Häfliger ✉︎
IOSI, I. Colombo ✉︎
AMG 193

MTA-Cooperative PRMT5 inhibitor
Phase 1, 1b, 2
Combination therapy
+/- Docetaxel
Indication
MTAP-deleted solid tumors
A Phase 1/1b/2 Study Evaluating The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy of AMG 193 Alone and in Combination with Docetaxel in Subjects with Advanced MTAP-Null Solid Tumors
Amgen protocol ID 20210023
Status Switzerland
Recruiting
Centers, PIs:
HUG, A. Addeo ✉︎
Inselspital, S.Häfliger ✉︎
IOSI, A. Stathis ✉︎
Xaluritamig
(AMG 509)


anti-STEAP1 XmAb
Phase 1
Mono- and combination therapy
Indication
mCRCP
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Amgen protocol ID 20180146
Status Switzerland
Recruiting
Centers, PIs:
KSSG, S. Fischer ✉︎
CHUV, D. Berthod ✉︎
KSGR, R. Cathomas ✉︎
IOSI, A. Vogl

For further questions relating to the study programme, please contact Carine Bast